Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Receivables - Accured (2022 - 2024)

Historic Receivables - Accured for Kezar Life Sciences (KZR) over the last 3 years, with Q3 2024 value amounting to $589000.0.

  • Kezar Life Sciences' Receivables - Accured changed N/A to $589000.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $589000.0, marking a year-over-year change of. This contributed to the annual value of $695000.0 for FY2023, which is 1020.67% down from last year.
  • Kezar Life Sciences' Receivables - Accured amounted to $589000.0 in Q3 2024.
  • In the past 5 years, Kezar Life Sciences' Receivables - Accured registered a high of $774000.0 during Q4 2022, and its lowest value of $374000.0 during Q2 2024.
  • Moreover, its 3-year median value for Receivables - Accured was $648000.0 (2024), whereas its average is $616000.0.
  • Within the past 5 years, the most significant YoY rise in Kezar Life Sciences' Receivables - Accured was 1020.67% (2023), while the steepest drop was 1020.67% (2023).
  • Over the past 3 years, Kezar Life Sciences' Receivables - Accured (Quarter) stood at $774000.0 in 2022, then dropped by 10.21% to $695000.0 in 2023, then fell by 15.25% to $589000.0 in 2024.
  • Its Receivables - Accured was $589000.0 in Q3 2024, compared to $374000.0 in Q2 2024 and $648000.0 in Q1 2024.